MedTrace Logo

Efficacy and Safety of Emodepside in Adults Infected With Strongyloidiasis Stercoralis

NCT06373835 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 202

Last updated 2024-11-20

No results posted yet for this study

Summary

Efficacy, safety and pharmacokinetics of ascending dosages of emodepside and in comparison to ivermectin against Strongyloidiasis stercoralis in adults: randomized stage II seamless adaptive controlled trials

Conditions

  • Strongyloides Stercoralis Infection
  • Strongyloidiasis

Interventions

DRUG

Emodepside

5 mg tablets of emodepside and matching placebo tablets, 3mg ivermectin

Sponsors & Collaborators

  • National Institute of Public Health, Vientiane, Laos

    collaborator OTHER

  • Swiss Tropical & Public Health Institute

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-20
Primary Completion
2024-09-21
Completion
2024-09-21

Countries

  • Laos

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06373835 on ClinicalTrials.gov